PT - JOURNAL ARTICLE AU - Annika Fendler AU - Lewis Au AU - Laura Amanda Boos AU - Fiona Byrne AU - Scott T.C. Shepherd AU - Ben Shum AU - Camille L. Gerard AU - Barry Ward AU - Wenyi Xie AU - Maddalena Cerrone AU - Georgina H. Cornish AU - Martin Pule AU - Leila Mekkaoui AU - Kevin W. Ng AU - Richard Stone AU - Camila Gomes AU - Helen R. Flynn AU - Ana Agua-Doce AU - Phillip Hobson AU - Simon Caidan AU - Mike Howell AU - Robert Goldstone AU - Mike Gavrielides AU - Emma Nye AU - Bram Snijders AU - James Macrae AU - Jerome Nicod AU - Adrian Hayday AU - Firza Gronthoud AU - Christina Messiou AU - David Cunningham AU - Ian Chau AU - Naureen Starling AU - Nicholas Turner AU - Jennifer Rusby AU - Liam Welsh AU - Nicholas van As AU - Robin Jones AU - Joanne Droney AU - Susana Banerjee AU - Kate Tatham AU - Shaman Jhanji AU - Mary O’Brien AU - Olivia Curtis AU - Kevin Harrington AU - Shreerang Bhide AU - Tim Slattery AU - Yasir Khan AU - Zayd Tippu AU - Isla Leslie AU - Spyridon Gennatas AU - Alicia Okines AU - Alison Reid AU - Kate Young AU - Andrew Furness AU - Lisa Pickering AU - Sonia Ghandi AU - Steve Gamblin AU - Charles Swanton AU - on behalf of the Crick COVID19 consortium AU - Emma Nicholson AU - Sacheen Kumar AU - Nadia Yousaf AU - Katalin Wilkinson AU - Anthony Swerdlow AU - Ruth Harvey AU - George Kassiotis AU - Robert Wilkinson AU - James Larkin AU - Samra Turajlic AU - on behalf of the CAPTURE consortium TI - Adaptive immunity to SARS-CoV-2 in cancer patients: The CAPTURE study AID - 10.1101/2020.12.21.20248608 DP - 2020 Jan 01 TA - medRxiv PG - 2020.12.21.20248608 4099 - http://medrxiv.org/content/early/2020/12/23/2020.12.21.20248608.short 4100 - http://medrxiv.org/content/early/2020/12/23/2020.12.21.20248608.full AB - There is a pressing need to characterise the nature, extent and duration of immune response to SARS-CoV-2 in cancer patients and inform risk-reduction strategies and preserve cancer outcomes. CAPTURE is a prospective, longitudinal cohort study of cancer patients and healthcare workers (HCWs) integrating longitudinal immune profiling and clinical annotation. We evaluated 529 blood samples and 1051 oronasopharyngeal swabs from 144 cancer patients and 73 HCWs and correlated with >200 clinical variables. In patients with solid cancers and HCWs, S1-reactive and neutralising antibodies to SARS-CoV-2 were detectable five months post-infection. SARS-CoV-2-specific T-cell responses were detected, and CD4+ T-cell responses correlated with S1 antibody levels. Patients with haematological malignancies had impaired but partially compensated immune responses. Overall, cancer stage, disease status, and therapies did not correlate with immune responses. These findings have implications for understanding individual risks and potential effectiveness of SARS-CoV-2 vaccination in the cancer population.Competing Interest StatementS.T. is funded by Cancer Research UK (grant reference number C50947/A18176), the National Institute for Health Research (NIHR) Biomedical Research Centre at the Royal Marsden Hospital and Institute of Cancer Research (grant reference number A109), the Kidney and Melanoma Cancer Fund of The Royal Marsden Cancer Charity, The Rosetrees Trust (grant reference number A2204), Ventana Medical Systems Inc (grant reference numbers 10467 and 10530), the National Institute of Health (US) and the Melanoma Research Alliance. S.T. has received speaking fees from Roche, Astra Zeneca, Novartis and Ipsen. S.T. has the following patents filed: Indel mutations as a therapeutic target and predictive biomarker PCTGB2018/051892 and PCTGB2018/051893 and Clear Cell Renal Cell Carcinoma Biomarkers P113326GB. J.L. has received research funding from Bristol-Myers Squibb, Merck, Novartis, Pfizer, Achilles Therapeutics, Roche, Nektar Therapeutics, Covance, Immunocore, Pharmacyclics, and Aveo, and served as a consultant to Achilles, AstraZeneca, Boston Biomedical, Bristol-Myers Squibb, Eisai, EUSA Pharma, GlaxoSmithKline, Ipsen, Imugene, Incyte, iOnctura, Kymab, Merck Serono, Nektar, Novartis, Pierre Fabre, Pfizer, Roche Genentech, Secarna, and Vitaccess. C.S. acknowledges grant support from Pfizer, AstraZeneca, Bristol Myers Squibb, Roche-Ventana, Boehringer-Ingelheim, Archer Dx Inc (collaboration in minimal residual disease sequencing technologies) and Ono Pharmaceutical, is an AstraZeneca Advisory Board member and Chief Investigator for the MeRmaiD1 clinical trial, has consulted for Pfizer, Novartis, GlaxoSmithKline, MSD, Bristol Myers Squibb, Celgene, AstraZeneca, Illumina, Genentech, Roche-Ventana, GRAIL, Medicxi, Bicycle Therapeutics, and the Sarah Cannon Research Institute, has stock options in Apogen Biotechnologies, Epic Bioscience, GRAIL, and has stock options and is co-founder of Achilles Therapeutics. Patents: C.S. holds European patents relating to assay technology to detect tumour recurrence (PCT/GB2017/053289); to targeting neoantigens (PCT/EP2016/059401), identifying patent response to immune checkpoint blockade (PCT/EP2016/071471), determining HLA LOH (PCT/GB2018/052004), predicting survival rates of patients with cancer (PCT/GB2020/050221), identifying patients who respond to cancer treatment (PCT/GB2018/051912), a US patent relating to detecting tumour mutations (PCT/US2017/28013) and both a European and US patent related to identifying insertion/deletion mutation targets (PCT/GB2018/051892). C.S. is Royal Society Napier Research Professor (RP150154). His work is supported by the Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001169), the UK Medical Research Council (FC001169), and the Wellcome Trust (FC001169). C.S. is funded by Cancer Research UK (TRACERx, PEACE and CRUK Cancer Immunotherapy Catalyst Network), Cancer Research UK Lung Cancer Centre of Excellence, the Rosetrees Trust, Butterfield and Stoneygate Trusts, NovoNordisk Foundation (ID16584), Royal Society Research Professorship Enhancement Award (RP/EA/180007), the NIHR BRC at University College London Hospitals, the CRUK-UCL Centre, Experimental Cancer Medicine Centre and the Breast Cancer Research Foundation, USA (BCRF). His research is supported by a Stand Up To Cancer-LUNGevity-American Lung Association Lung Cancer Interception Dream Team Translational Research Grant (SU2C-AACR-DT23-17). Stand Up To Cancer is a program of the Entertainment Industry Foundation. Research grants are administered by the American Association for Cancer Research, the Scientific Partner of SU2C. C.S. also receives funding from the European Research Council (ERC) under the European Unions Seventh Framework Programme (FP7/2007-2013) Consolidator Grant (FP7-THESEUS-617844), European Commission ITN (FP7-PloidyNet 607722), an ERC Advanced Grant (PROTEUS) from the European Research Council under the European Unions Horizon 2020 research and innovation programme (835297) and Chromavision from the European Unions Horizon 2020 research and innovation programme (665233). L.P. has received research funding from Pierre Fabre, and honoria from Pfizer, Ipsen, Bristol-Myers Squibb, and EUSA Pharma. A.F., L.A., L.A.B., F.B., S.T.C.S., A.S., B.S, BW, CG, WX have no conflicts of interest to declare.Clinical TrialNCT03226886Funding StatementThe CAPTURE study is sponsored by The Royal Marsden NHS Foundation Trust and funded from a grant from The Royal Marsden Cancer Charity. The Francis Crick Institute receives its core funding from Cancer Research UK (CRUK) (FC010110), the UK Medical Research Council (FC010110), and the Wellcome Trust (FC010110). For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. TRACERx Renal is partly funded by the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at the Royal Marsden Hospital and Institute of Cancer Research (ICR) (A109).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:CAPTURE was approved as a substudy of TRACERx Renal (NCT03226886). TRACERx Renal was initially approved by NRES Committee London Fulham on 17/01/2012. The TRACERx Renal sub-study CAPTURE was submitted as part of Substantial Amendment 9 and approved by London - Fulham Research Ethics Committee on 01/05/2020 and the Health Research Authority on 30/04/2020. CAPTURE is performed in accordance with the ethical principles in the Declaration of Helsinki, Good Clinical Practice and applicable regulatory requirements.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRequest for further information or for resources and reagents should be directed and will be fulfilled by the lead contact, Samra Turajlic (samra.turajlic@crick.ac.uk)